Inquiry Basket
Loading ......
Panitumumab, marketed as Vectibix, represents a significant advance in targeted cancer therapy. As a fully human monoclonal antibody, it offers a sophisticated approach to treating metastatic colorectal cancer while minimizing the immunogenicity concerns associated with earlier chimeric antibodies. However, the successful clinical use of any biologic therapeutic depends on rigorous monitoring. Researchers and clinicians rely on specialized ELISA kits to measure drug concentrations and detect unwanted immune responses. The epidermal growth factor receptor (EGFR) pathway is a key driver in many solid tumors. When this receptor is overexpressed or mutated, it can promote uncontrolled cell growth, angiogenesis, and resistance to chemotherapy. Panitumumab works by binding to the extracellular domain of EGFR with high affinity, blocking the natural ligands from activating the receptor. This prevents receptor dimerization and downstream signaling through pathways like RAS-RAF-MEK and PI3K-AKT that are essential for tumor survival and proliferation. For patients with wild-type RAS genes, this targeted blockade can be highly effective.
Figure 1.Panitumumab ELISA Solutions for Pharmacokinetics and Immunogenicity Testing.
Colorectal cancer arises from the colonic or rectal epithelium via an adenoma-to-carcinoma sequence driven by genetic and epigenetic alterations, including APC, KRAS, TP53, and PIK3CA mutations, microsatellite instability, and aberrant DNA methylation. A subset of tumors with wild-type RAS genes is susceptible to EGFR-targeted therapies like panitumumab. EGFR, a transmembrane receptor tyrosine kinase overexpressed in many colorectal cancers, activates downstream RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways that drive proliferation, survival, angiogenesis, and metastasis. Activating KRAS or NRAS mutations constitutively activate these pathways downstream of EGFR, rendering receptor blockade ineffective; thus, RAS mutation status guides patient selection for panitumumab. Panitumumab binds with high affinity to EGFR domain III, competitively blocking EGF and TGF-α ligands. This prevents receptor dimerization, autophosphorylation, and downstream signaling, inhibiting tumor proliferation, inducing apoptosis, and suppressing angiogenesis. Panitumumab also mediates immune effector functions, though its IgG2 isotype limits CDC and ADCC relative to IgG1 antibodies.The major clinical applications of panitumumab include:
Despite the well-established clinical efficacy of panitumumab, interpatient variability in drug exposure is substantial. Factors contributing to pharmacokinetic variability include body weight and composition, tumor burden, circulating soluble EGFR concentrations, renal function, hepatic metabolism, and concomitant medications. Tumor bulk can function as a peripheral distribution compartment for panitumumab, with high EGFR-expressing tumors sequestering considerable drug quantities and thereby reducing systemic circulating levels. Elevated soluble EGFR shed from tumor cells into the bloodstream can further bind panitumumab, modulating the ratio of free to total drug and complicating the interpretation of drug exposure metrics. Furthermore, the development of anti-drug antibodies in a subset of patients can accelerate drug clearance and diminish bioavailability, leading to subtherapeutic exposure and attenuated clinical response. The distinction between free and total panitumumab measurements is analytically critical: free drug assays quantify the pharmacologically active, unbound fraction available for receptor engagement at the tumor cell surface, while total drug assays capture both free and complexed panitumumab, providing a comprehensive picture of overall drug burden including antibody bound to circulating target or anti-drug antibodies. A meaningful discrepancy between free and total concentrations can signal the presence of neutralizing antibodies or elevated soluble EGFR, informing clinical decisions regarding dose adjustment or therapeutic switch.
Accurate bioanalytical measurement of panitumumab concentrations and anti-drug antibodies constitutes an indispensable pillar of modern colorectal cancer patient care and biopharmaceutical development. The Panitumumab ELISA Kit portfolio delivers a comprehensive immunoassay solution to resolve key analytical challenges including free versus total drug quantification, immunogenicity detection, and pharmacokinetic profiling. These kits are engineered with optimized capture and detection reagent pairs, validated across human clinical serum and plasma matrices, and designed to generate reproducible, quantitative or qualitative data acceptable for clinical trial submissions and translational research reporting. Each kit employs a solid-phase sandwich ELISA format in which standards or samples are incubated in microtiter plates pre-coated with a capture reactant specific to panitumumab, followed by HRP-conjugated detection probe, TMB substrate development, and acidic stop solution termination, with color intensity proportional to the analyte concentration.
| Kits | Details |
| Free Panitumumab ELISA Kit | Quantitative detection of free panitumumab in human serum and plasma for pharmacokinetic studies, free drug monitoring, and individualized dose optimization in colorectal cancer therapy. |
| Total Panitumumab ELISA Kit | Quantitative detection of total (free and bound) panitumumab in human serum and plasma for comprehensive pharmacokinetic profiling, drug exposure assessment, and free-versus-total comparative analysis. |
| Anti-Panitumumab ELISA Kit | Qualitative detection of anti-panitumumab antibodies in human serum and plasma for immunogenicity assessment, ADA screening, and evaluation of treatment-emergent immune responses. |
Panitumumab represents a major therapeutic advance for patients with RAS wild-type metastatic colorectal cancer. Its high affinity for EGFR and fully human structure provide efficacy with reduced immunogenicity. However, the successful use of this biologic depends on rigorous monitoring of pharmacokinetics and immunogenicity. Free Panitumumab, Total Panitumumab, and Anti-Panitumumab ELISA kits provide the essential analytical tools for this monitoring. These assays enable researchers to measure drug concentrations, assess the body's immune response, and ensure that patients receive the full benefit of therapy. As the understanding of EGFR biology continues to advance and new therapeutic strategies emerge, these ELISA solutions will remain indispensable for both drug development and clinical research.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-JY25290 | Anti-Pramlintide ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIA-JY25302 | Pramlintide ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
Loading ......
